Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

NCT05974410 is registered in ClinicalTrials.gov with AVM Biotechnology Inc as lead sponsor.

NCT NCT05974410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05974410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
Lead sponsor
AVM Biotechnology Inc
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, breast cancer, cancer, desmoplastic round cell sarcoma, esophageal andeocarcinoma, gastric cancer, glioblastoma, hodgkin lymphoma, mixed phenotype aml, non-hodgkin lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, spindle cell sarcoma, squamous cell carcinoma, tumor, brain, tumor, solid